Ono Pharmaceutical said on August 20 that its BRAF inhibitor Braftovi (encorafenib) has been approved in South Korea for the treatment of certain patients with colorectal cancer in combination with Erbitux (cetuximab), an EGFR inhibitor. The drug was granted approval…
To read the full story
Related Article
- Ono’s Colorectal Cancer Med Braftovi Widens Label in South Korea
January 14, 2026
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





